Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Technology Laboratories

This article was originally published in The Gray Sheet

Executive Summary

Preliminary second quarter results put revenues at $75 mil., down from $77 mil. in the year-ago quarter and "below management expectations," the firm says in a July 13 press release. Sales suffered from "the uncertain impact of U.S. health care reform legislation." ATL expects to report a loss of $1.5 mil. to $2 mil. due to the revenue shortfall, higher R&D costs, and expenses associated with the introduction of the Extended Signal Processing upgrade for the Ultramark 9 ultrasound system with High Definition Imaging ("The Gray Sheet" April 26, I&W-2). For the second quarter of 1992, the firm recorded a loss of $2.1 mil.; the loss included $5 mil. in nonrecurring charges related to the division of Westmark International into two companies: ATL and SpaceLabs Medical. The firm also reports that as of the close of the second quarter, it has repurchased 469,000 shares of stock under a 1 mil. share repurchase program, bringing outstanding shares to 10.8 mil....

You may also be interested in...



Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee

Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel